RxDoctor Payments Data

Sarah Garand

Family · Charleston, WVNPI 1891247086

Payments from drug & device makers

$1,033in general payments, 2019–2025

Across 43 payments — averaging $24.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$400
  • AbbVie$176
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$129
  • Otsuka America Pharmaceutical, Inc.$105
  • E.r. Squibb & Sons, L.L.C.$82
  • Johnson & Johnson$78
  • plus $63 from 3 others

What the payments were for

  • Food & beverage$98695%
  • Education$475%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,033 in reported general payments places this provider in the 65th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$8,974
Medicare patients
29
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate30$102,447
AustedoDeutetrabenazine14$76,867
VraylarCariprazine Hcl31$44,667
Chlorpromazine Hcl13$4,478
Aripiprazole64$2,332
Vilazodone Hcl15$1,479
Lurasidone Hcl14$1,477
Clonazepam107$1,457
Fluoxetine Hcl102$1,251
Quetiapine Fumarate115$1,197
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl20$1,036
Risperidone59$911
Oxcarbazepine21$895
Hydroxyzine Pamoate69$862
Alprazolam106$801

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$78$102,44730 claims
Teva Pharmaceuticals USA, Inc.Austedo$20$76,86714 claims
AbbVieVraylar$176$44,66731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,507 family providers in West Virginia.

Other family in Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →